So you’re postulating that it’s unlikely someo

So you’re postulating that it’s unlikely someone would want to partner with another company for just one indication? It literally happened to Cytodyn already for US rights to only HIV. You can counter with “well they’re not big pharma”. Sure, there’s some credence to your thoughts that they’ll want the whole enchilada. Who wouldn’t? But they absolutely do partner for indications and in the case of Cytodyn where there’s no interest in a buyout that doesn’t cover all of LL’s potential, the cost is too great. However a large piece of a 25 billion dollar NASH market with hopes that they can weasel their way into more of the platform is absolutely worth their while.